These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2928345)

  • 1. Striatal phosphoproteins in Parkinson disease and progressive supranuclear palsy.
    Girault JA; Raisman-Vozari R; Agid Y; Greengard P
    Proc Natl Acad Sci U S A; 1989 Apr; 86(7):2493-7. PubMed ID: 2928345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
    Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
    Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
    Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
    Im JH; Chung SJ; Kim JS; Lee MC
    J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy.
    Pierot L; Desnos C; Blin J; Raisman R; Scherman D; Javoy-Agid F; Ruberg M; Agid Y
    J Neurol Sci; 1988 Sep; 86(2-3):291-306. PubMed ID: 2975699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.
    Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS
    J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARPP-21, a cAMP-regulated phosphoprotein enriched in dopamine-innervated brain regions: tissue distribution and regulation of phosphorylation in rat brain.
    Girault JA; Walaas SI; Hemmings HC; Greengard P
    Neuroscience; 1990; 37(2):317-25. PubMed ID: 1966823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
    J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotensin receptors in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study in basal ganglia.
    Chinaglia G; Probst A; Palacios JM
    Neuroscience; 1990; 39(2):351-60. PubMed ID: 1965015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.
    Tong J; Ang LC; Williams B; Furukawa Y; Fitzmaurice P; Guttman M; Boileau I; Hornykiewicz O; Kish SJ
    Neurobiol Dis; 2015 Oct; 82():243-253. PubMed ID: 26102022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man.
    Raisman-Vozari R; Girault JA; Moussaoui S; Feuerstein C; Jenner P; Marsden CD; Agid Y
    Brain Res; 1990 Jan; 507(1):45-50. PubMed ID: 2105823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free-water imaging in Parkinson's disease and atypical parkinsonism.
    Planetta PJ; Ofori E; Pasternak O; Burciu RG; Shukla P; DeSimone JC; Okun MS; McFarland NR; Vaillancourt DE
    Brain; 2016 Feb; 139(Pt 2):495-508. PubMed ID: 26705348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of striatal high affinity NGF binding sites in progressive supranuclear palsy but not in Parkinson's disease.
    Villares J; Strada O; Faucheux B; Javoy-Agid F; Agid Y; Hirsch EC
    Neurosci Lett; 1994 Nov; 182(1):59-62. PubMed ID: 7891888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain monoamines in progressive supranuclear palsy--comparison with idiopathic Parkinson's disease.
    Hornykiewicz O; Shannak K
    J Neural Transm Suppl; 1994; 42():219-27. PubMed ID: 7964689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram.
    Chinaglia G; Landwehrmeyer B; Probst A; Palacios JM
    Neuroscience; 1993 Jun; 54(3):691-9. PubMed ID: 8332256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfonylurea binding sites in normal human brain and in Parkinson's disease, progressive supranuclear palsy and Huntington's disease.
    Holemans S; Javoy-Agid F; Agid Y; De Paermentier F; Laterre EC; Maloteaux JM
    Brain Res; 1994 Apr; 642(1-2):327-33. PubMed ID: 8032896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy.
    Federico F; Simone IL; Lucivero V; De Mari M; Giannini P; Iliceto G; Mezzapesa DM; Lamberti P
    J Neurol Neurosurg Psychiatry; 1997 Mar; 62(3):239-42. PubMed ID: 9069478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARPP-21, a cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. I. Purification and characterization of the protein from bovine caudate nucleus.
    Hemmings HC; Greengard P
    J Neurosci; 1989 Mar; 9(3):851-64. PubMed ID: 2538584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.